Menumenu
  • Home
  • Resource Library

Resource Library

publications • bibliographies • white papers

All Publications

  • The availability of information on impaired renal function in the community pharmacy, a descriptive pilot study.Abstract

    Aim

    Smits E, Houben E, de Smet PAGM, Szerencsi K, van Herk-Sukel MPP, Herings RMC, Teichert M. J Nephrol Renal Ther. 2016 2 003.
  • Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the NetherlandsAbstract

    BACKGROUND: Most randomised clinical trials typically exclude a significant proportion of asthma patients, including those at higher risk of adverse events, with comorbidities, obesity, poor inhaler technique and adherence, or smokers. However, thee patients might differentially benefit from extrafine-particle inhaled corticosteroids (ICS)

    van der Molen T, Postma DS, Martin RJ, Herings RM, Overbeek JA, Thomas V, Miglio C, Dekhuijzen R, Roche N, Guilbert T, Israel E, van Aalder en W, Hillyer EV, van Rysewyk S, Price DB. BMC Pulm Med. 2016 16 (1): 80.
  • Identifying Cases of Type 2 Diabetes in Heterogeneous Data Sources: Strategy from the EMIF ProjectAbstract

    Due to the heterogeneity of existing European sources of observational healthcare data, data source-tailored choices are needed to execute multi-data source, multi-national epidemiological studies. This makes transparent documentation paramount. Inthis proof-of-concept study, a novel standard data derivation procedure was tested in a set of heterogeneous data sources

    Roberto G, Leal I, Sattar N, Loomis AK, Avillach P, Egger P, van Wijngaarden R, Ansell D, Reisberg S, Tammesoo ML, Alavere H, Pasqua A, Peder sen L, Cunningham J, Tramontan L, Mayer MA, Herings R, Coloma P, Lapi F, Sturkenboom M, van der Lei J, Schuemie MJ, Rijnbeek P, Gini R. PLoS One. 2016 11 (8): e0160648.
  • Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control studyAbstract

    OBJECTIVES: To investigate the cardiovascular safety of non-steroidal anti-inflammatory drugs (NSAIDs) and estimate the risk of hospital admission for heart failure with use of individual NSAIDs. DESIGN: Nested case-control study. SETTING: Five poplation based healthcare databases from four European countries (the Netherlands, Italy, Germany, and the United Kingdom)

    Arfe A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T, Garbe E, Herings R, Straatman H, Schade R, Villa M, Lucchi S, Valkhoff V, Romio S, Thiessard F, Schuemie M, Pariente A, Sturkenboom M, Corrao G, SafetyofNon-steroidalAnti-inflammatoryDrugsProject Consortium. BMJ. 2016 354 i4857.
  • Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countriesAbstract

    OBJECTIVE: To evaluate the association between pioglitazone use and bladder cancer risk in patients with type 2 diabetes. DESIGN: Retrospective cohort study using propensity score matched cohorts. SETTINGS: Healthcare databases from Finland, the Neherlands, Sweden, and the United Kingdom. Data comprised country specific datasets of linked records on prescriptions, hospitals, general practitioners, cancer, and deaths

    Korhonen P, Heintjes EM, Williams R, Hoti F, Christopher S, Majak M, Kool-Houweling L, Strongman H, Linder M, Dolin P, Bahmanyar S. BMJ. 2016 354 i3903.
  • Explaining the Decline in Coronary Heart Disease Mortality in the Netherlands between 1997 and 2007Abstract

    OBJECTIVE: We set out to determine what proportion of the mortality decline from 1997 to 2007 in coronary heart disease (CHD) in the Netherlands could be attributed to advances in medical treatment and to improvements in population-wide cardiovascuar risk factors. METHODS: We used the IMPACT-SEC model

    Koopman C, Vaartjes I, van Dis I, Verschuren WM, Engelfriet P, Heintjes EM, Blokstra A, Deeg DJ, Visser M, Bots ML, O'Flaherty M, Capewell S. PLoS One. 2016 11 (12): e0166139.
  • Anticoagulant Treatment after VTE in the Netherlands: A Retrospective Cohort StudyAbstract

    Background: The aim of the study was to describe initial anticoagulant treatment after venous thromboembolism (VTE) and relate this to the underlying risk factors, guidelines and recurrence rates.

    Bezemer ID, van den Berg EJ, Herings RMC, Bamber L, Penning-van Beest FJA, Folkerts K, Coppens M. J J Hemato. 2016 2 (2): 030.
  • Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasterideAbstract

    BACKGROUND: Previous studies have suggested a greater benefit for various outcomes in men diagnosed with benign prostatic hyperplasia (BPH) who are treated with dutasteride than for men treated with finasteride. This study investigates whether theates of BPH-related prostate surgery and acute urinary retention (AUR) differ between dutasteride and finasteride users in the Netherlands

    Kuiper JG, Bezemer ID, Driessen MT, Vasylyev A, Roehrborn CG, Penning-van Beest FJ, Herings RM. BMC Urol. 2016 16 (1): 53.
  • Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal DetectionAbstract

    BACKGROUND AND OBJECTIVE: Spontaneous reporting systems (SRSs) remain the cornerstone of post-marketing drug safety surveillance despite their well-known limitations. Judicious use of other available data sources is essential to enable better detecion, strengthening and validation of signals. In this study, we investigated the potential of electronic healthcare records (EHRs) to be used alongside an SRS as an independent system, with the aim of improving signal detection

    Pacurariu AC, Straus SM, Trifiro G, Schuemie MJ, Gini R, Herings R, Mazzaglia G, Picelli G, Scotti L, Peder sen L, Arlett P, van der Lei J, Sturkenboom MC, Coloma PM. Drug Saf. 2015 Dec; 38 (12): 1201-10.
  • Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the NetherlandsAbstract

    AIM: Palivizumab is reported to be effective in reducing respiratory syncytial virus hospitalisation. Its licensed uses include infants younger than six months of age, born before 35 weeks of gestation or under two years old with congenital heart dsease or bronchopulmonary dysplasia. We redressed lack of research in the Netherlands by studying whether infants who met the licensed indications received the drug

    Kool-Houweling LM, Penning-van Beest FJ, Bezemer ID, van Lingen RA, Herings RM. Acta Paediatr. 2015 Sep; 104 (9): 927-32.